The Use of Liposomes as Carriers of Lipophilic Anthracycline Antibiotics

References

• Moscow JA, Cowan KH. Multidrug resistance. J Natl Cancer Inst. 1988; 80: 14–20
   PubMed Web of Science ®Google Scholar
• Tritton TR, Posada JA. The role of the cell surface membrane in adriamycin resistance. Resistance to antineoplastic drugs, D Kessel. CRC Press, Boca Raton, FL 1989; 109–126
   Google Scholar
• Chan HSL, Thomer PS, Haddad G. Immunohistochemical detection of P-glycoprotein: prognostic correlation in solft tissue sarcoma of childhood. J Clin Oncol 1990; 8: 689–704
   PubMed Web of Science ®Google Scholar
• Chan HSL, Haddad G., Thomer PS. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991; 325: 1608–1614
   PubMed Web of Science ®Google Scholar
• Herman EH, Rahman A., Ferrans VJ, Vick JA, Schein PS. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res 1983; 43: 5427–5432
   PubMed Web of Science ®Google Scholar
• Rahman A., Treat J, Roh JK, Potkul LA, Alvord WG, Forst D, Wolley PV. A Phase I clinical trial and phramacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 1990; 8: 1093–1100
   PubMed Web of Science ®Google Scholar
• Gabizon A., Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood enhanced uptake by tumors. Proc Natl Acad Sci USA 1988; 85: 6949–6953
   PubMed Web of Science ®Google Scholar
• Gabizon A., Price DC, Huberty J, Bresalier RS, Papahadjopoulos D. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. Cancer Res 1990; 50: 6371–6378
   PubMed Web of Science ®Google Scholar
• Gabizon A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 1992; 52: 891–896
   PubMed Web of Science ®Google Scholar
• Fan D, Bucana CD, O'Brian CA, Zwelling LA, Seid C., Fidler IJ. Enhancement of murine tumor cell sensitivity to adriamycin by presentation of the drug in phosphatidylcholine-phosphatidylserine liposomes. Cancer Res 1990; 50: 3619–3626
   PubMed Web of Science ®Google Scholar
• Oudard S, Thierry A., Jorgensen TJ, Rahman A. Sensitization of multidrug resistant colon cancer cells to doxorubicin encapsulated in liposomes. Cancer Chemother Pharmacol 1991; 28: 259–265
   PubMed Web of Science ®Google Scholar
• Warren L, Jardillier JC, Malarska A., Akeli MG. Increased accumulation of drugs in multidrug-resistant cells induced by liposomes. Cancer Res 1992; 53: 3241–3245
   Google Scholar
• Rahman A., Husain SR, Siddiqui J, Verma M., Agresti M., Center M., Safa AR, Glazer RI. Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells. J Natl Cancer Inst. 1992; 84: 1909–1914
   PubMed Web of Science ®Google Scholar
• Rahman A., Mickisch G., Pastan I, Gottesman M. Liposome encapsulated doxorubicin (LED) circumvents doxorubicin (DOX) resistance in MDR transgenic mice. Proceedings AACR 33:471, 1992
   Google Scholar
• Coley HM, Twentyman PR, Workman P. 9-alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. Eur J Cancer 1990; 6: 665–667
   Google Scholar
• Horichi N, Tapiero H., Sugimoto Y, Bungo M., Nishiyama M., Fourcade A., Lampidids TJ, Kasahara K, Sasaki Y, Takahashi T, Saijo N. 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and double-strand breaks. Cancer Res 1990; 50: 4698–4701
   PubMed Web of Science ®Google Scholar
• Acton EM, Tong GL, Mosher CW, Wolgemuth RL. Intensely potent morpholinyl anthracyclines. J Med Chem 1984; 27: 638–645
   PubMed Web of Science ®Google Scholar
• Coley HM, Twentyman PR, Workman P. Identification of anthracyclines and related agents that retain preferential activity over Adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A. Cancer Chemother Pharmacol 1989; 24: 284–290
   PubMed Web of Science ®Google Scholar
• Ganapayhi R., Grabowski D, Sweatman TW, Seshadri R., Israel M. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumors: cellular pharmacology and characterization of cross-resistance in vitro and in vivo. Br J Cancer 1989; 60: 819–826
   PubMed Web of Science ®Google Scholar
• Israel M., Sweatman TW, Seshadri R., Koseki Y. Comparative uptake and retention of adriamycin and N-benzyladriamycin-14-valerate in human CEM leukemic lymphocyte cell cultures. Cancer Chemother Pharmacol 1989; 25: 177–183
   PubMed Web of Science ®Google Scholar
• Lothstein L, Sweatman TW, Dockter ME, Israel M. Resistance to N-benzyladriamycin-14-valerate in mouse J774.2 cells: P-glycoprotein expression without reduced N-benzyladriamycin-14-valerate accumulation. Cancer Res 1992; 52: 3409–3417
   PubMed Web of Science ®Google Scholar
• Barbieri B, Giuliani FC, Bordoni T, Casazza AM, Geroni C., Bellini O, Suarato A., Gioia B, Penco S, Arcamone F. Chemical and biological characterization of 4'-iodo-4'-deoxydoxorubicin. Cancer Res 1987; 47: 4001–4006
   PubMed Web of Science ®Google Scholar
• Priebe W, Van NT, Burke TG, Perez-Soler R. Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity. Anticancer Drugs 1993; 4: 37–48
   PubMed Web of Science ®Google Scholar
• Perez-Soler R., Priebe W. Anthracycline antibiotics with high liposome entrapment: structural features and biological activity. Cancer Res. 1990; 50: 4260–4266
   PubMed Web of Science ®Google Scholar
• Horton D, Priebe W. 4-demethoxy-3'-desamino-2'-halo anthracycline and pharmaceutical composition containing same. U.S. Patent 4,537,882, August 1985; 27
   Google Scholar
• Zou Y, Hayman A., Priebe W, Perez-Soler R. Quantitative analysis of the lipophilic doxorubicin analogue Annamycin in plasma and tissue samples by reverse-phase chromatography. J Pharm Sciences, (in press)
   Google Scholar
• Zou Y, Priebe W, Ling YH, Perez-Soler R. Organ distribution and tumor uptake of Annamycin, a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesicles. Cancer Chemother Pharmacol 1993; 32: 190–196
   PubMed Web of Science ®Google Scholar
• Ling YH, Priebe W, Yang LY, Burke TG, Pommier Y, Perez-Soler R. In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by Annamycin, an anthracycline derivative with high affinity for lipid membranes. Cancer Res, in press
   Google Scholar
• Perez-Soler R., Ling YH, Zou Y, Priebe W. Cellular pharmacology of the non-cross resistant anthracycline annamycin in KB and multidrug resistant KB-V1 cells, Submitted for publication
   Google Scholar
• Perez-Soler R., priebe W. Liposomal formulation and antitumor activity of 14-O-palmitoyl hydroxyrubicin. Cancer Chemother Pharmacol 1992; 30: 267–271
   PubMed Web of Science ®Google Scholar
• Zou Y, Ling YH, Van NT, Priebe W, Perez-Soler R. Antitumor activity of the lipophilic and non-cross resistant anthracycline annamycin entrapped in liposomes, Submitted for publication
   Google Scholar